Debra L Richardson MD
Gynecologic Oncology
Associate Professor, Gynecologic Oncology at Stephenson Cancer Center
Join to View Full Profile
800 NE 10th StOklahoma City, OK 73104
Phone+1 405-271-7770
Dr. Richardson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Ohio State University/Mt Carmel HospitalFellowship, Gynecologic Oncology, 2006 - 2009
University of ConnecticutResidency, Obstetrics and Gynecology, 2001 - 2005
New York Medical CollegeClass of 2001
Certifications & Licensure
OK State Medical License 2017 - 2025
TX State Medical License 2009 - 2020
MN State Medical License 2005 - 2011
OH State Medical License 2006 - 2009
American Board of Obstetrics and Gynecology Obstetrics & Gynecology- American Board of Obstetrics and Gynecology Gynecologic Oncology
Clinical Trials
- Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer Start of enrollment: 2020 Jun 29
Roles: Contact
- A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. Start of enrollment: 2022 Jul 25
Roles: Principal Investigator
- Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) Start of enrollment: 2022 Aug 31
Roles: Contact, Principal Investigator
- Join now to see all
Publications & Presentations
PubMed
- Immune modulation in solid tumors: a phase 1b study of RO6870810 (BET inhibitor) and atezolizumab (PD-L1 inhibitor).Daniel Marbach, Jurriaan Brouer-Visser, Laura Brennan, Sabine Wilson, Iakov I Davydov
BMC Cancer. 2025-03-18 - Incorporation of triapine (T) to cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial.Charles A Leath 3rd, Wei Deng, Loren K Mell, Debra L Richardson, Joan L Walker
Gynecologic Oncology. 2025-03-17 - Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer.Oladapo O Yeku, Minal Barve, Winston W Tan, Judy Wang, Amita Patnaik
Journal for Immunotherapy of Cancer. 2025-03-13
Press Mentions
Mersana Therapeutics to Provide Update on the Progress of Its UpRi Clinical Development Strategy and Report Interim Data from the Ovarian Cancer Expansion Cohort of the UpRi Phase I StudySeptember 1st, 2021- Sarah Cannon to Present Latest Cancer Research Insights at 2021 ASCO® Annual MeetingJune 4th, 2021
- Group Is Established to Connect, Inspire and Empower UCI Women in TechnologyAugust 12th, 2020
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
